Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
SHR117887 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the
efficacy and safety of SHR117887 in combination therapy with Metformin in patients with Type
2 Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control